About Cyclic AMP-responsive element-binding protein 1
Cyclic AMP-responsive element-binding protein 1 (CREB1) is a protein
from Homo sapiens identified by UniProt accession
P16220, 327 residues long.
MolForge cross-references it against 0 known binders and
756 disease associations.
Target properties
| Protein name | Cyclic AMP-responsive element-binding protein 1 |
|---|
| UniProt accession | P16220 |
|---|
| Gene | CREB1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 327 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (756)
Diseases linked to this target (Open Targets).
- infectious disease · score 0.46
- neurodegenerative disease · score 0.46
- Alzheimer disease · score 0.38
- clear cell sarcoma · score 0.37
- multiple sclerosis · score 0.37
- Parkinson disease · score 0.37
- esophageal adenocarcinoma · score 0.37
- gastric carcinoma · score 0.37
- breast ductal adenocarcinoma · score 0.37
- bile duct carcinoma · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P16220-F1 | alphafold | PREDICTED | 61.07 | — |
Amino-acid sequence (327 residues)
MTMESGAENQ QSGDAAVTEA ENQQMTVQAQ PQIATLAQVS MPAAHATSSA PTVTLVQLPN GQTVQVHGVI QAAQPSVIQS PQVQTVQIST IAESEDSQES VDSVTDSQKR REILSRRPSY RKILNDLSSD APGVPRIEEE KSEEETSAPA ITTVTVPTPI YQTSSGQYIA ITQGGAIQLA NNGTDGVQGL QTLTMTNAAA TQPGTTILQY AQTTDGQQIL VPSNQVVVQA ASGDVQTYQI RTAPTSTIAP GVVMASSPAL PTQPAEEAAR KREVRLMKNR EAARECRRKK KEYVKCLENR VAVLENQNKT LIEELKALKD LYCHKSD
Explore Cyclic AMP-responsive element-binding protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets